Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics was written by Matsukawa, Yoshihisa;Takai, Shun;Majima, Tsuyoshi;Funahashi, Yasuhito;Kato, Masashi;Yamamoto, Tokunori;Gotoh, Momokazu. And the article was included in Therapeutic Advances in Urology in 2018.SDS of cas: 160970-54-7 This article mentions the following:
The aim of this research was to investigate intermediate-term effects of silodosin on lower urinary tract functions and symptoms in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) according to prostate size, using urodynamics. A total of 70 untreated outpatients with a prostate volume <40 mL [small prostate (SP) group] and 70 with prostate volume 鈮?0 mL [large prostate (LP) group] were prospectively enrolled and treated by monotherapy with silodosin for 24 mo. Changes in parameters from baseline to 3 mo and 24 mo after silodosin administration were assessed based on LUTS, voiding and storage function. In addition, withdrawal rates of silodosin due to insufficient effects were compared between the two groups and factors to influence the withdrawal were investigated. The International Prostate Symptom Score (IPSS), bladder outlet obstruction index (BOOI), and detrusor overactivity (DO) improved significantly for the 2-yr follow up in both groups as compared with the baseline. Improvement rates in the IPSS and BOOI at 3 mo were maintained until 24 mo in the SP group, but decreased in the LP group. Dropout rate due to unsatisfactory effects was significantly higher in the LP group (20% vs. 8.6%). Silodosin significantly improved lower urinary tract functions for 2 years in patients with LUTS/BPH, regardless of prostate size. In the experiment, the researchers used many compounds, for example, (-)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1H-indole-7-carboxamide (cas: 160970-54-7SDS of cas: 160970-54-7).
(-)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1H-indole-7-carboxamide (cas: 160970-54-7) belongs to indole derivatives. Indole, first isolated in 1866, and it is commonly synthesized from phenylhydrazine and pyruvic acid, although several other procedures have been discovered. Moreover, it is known that it controls biofilm formation. However, the role of indole in the cell has not been fully elucidated.SDS of cas: 160970-54-7
Referemce:
Indole alkaloid derivatives as building blocks of natural products from聽Bacillus thuringiensis聽and聽Bacillus velezensis聽and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles